(NASDAQ: AYTU) Aytu Biopharma's forecast annual revenue growth rate of 26.28% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.98%.
Aytu Biopharma's revenue in 2026 is $57,570,000.On average, 5 Wall Street analysts forecast AYTU's revenue for 2027 to be $752,704,263, with the lowest AYTU revenue forecast at $718,050,331, and the highest AYTU revenue forecast at $779,305,964. On average, 5 Wall Street analysts forecast AYTU's revenue for 2028 to be $963,290,197, with the lowest AYTU revenue forecast at $809,352,412, and the highest AYTU revenue forecast at $1,073,685,084.
In 2029, AYTU is forecast to generate $1,288,356,900 in revenue, with the lowest revenue forecast at $1,237,826,708 and the highest revenue forecast at $1,326,281,711.